Citation Impact
Citing Papers
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
2013
Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
2012
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2009
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
2012
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
2010
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells
2016
Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
2009
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
2012
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
2013
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
2012
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
2010
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
mRNA-based dendritic cell vaccines
2014
New drugs in melanoma: It’s a whole new world
2011
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
2010
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
2010
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
2013
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
2013
Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach
2010
The European Regulatory Environment of RNA-Based Vaccines
2016
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
2014 StandoutNatureNobel
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
2016
The Human T Cell Response to Melanoma Antigens
2006
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
2010
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma
2011
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
2012
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
2010
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Development trends for human monoclonal antibody therapeutics
2010
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
2017
CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory Cells
2010
Colorectal cancer
2019 Standout
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
2014
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
2016
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
2017
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
2009
Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
2010 StandoutNobel
Chemotherapy Maintenance
2016
Immunotherapy in colorectal cancer: rationale, challenges and potential
2019
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
2012
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
2018
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
The ReNAissanCe of mRNA-based cancer therapy
2014
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
CTLA-4 blockade: therapeutic potential in cancer treatments
2010
Improved Endpoints for Cancer Immunotherapy Trials
2010
Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression
2023
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
2010
Advances in systemic treatment of melanoma
2010
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
2016
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
mRNA transcript therapy
2014 StandoutNobel
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
2015
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
2013
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
2014
Primary brain tumours in adults
2012 Standout
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
Revealing the world of RNA interference
2004 StandoutNatureNobel
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
2012
Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients
2014
Therapeutic Cancer Vaccines
2013
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
2013
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
2012
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Ipilimumab-induced acute severe colitis treated by infliximab
2013
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
2013 Nature
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
2015
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
2014
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
mRNA Cancer Vaccines
2016
Ipilimumab in patients with cancer and the management of dermatologic adverse events
2014
Cytokines in clinical cancer immunotherapy
2018
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
2010
Development of Catheter-Based Procedures for Transducing the Isolated Rabbit Liver with Plasmid DNA
2002
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
2019 Nobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
2015
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
2010
Managing Immune Checkpoint-Blocking Antibody Side Effects
2015
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
2013
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Human Tumor Antigens and Cancer Immunotherapy
2015
The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses
2011
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Therapeutic Targeting of the Tumor Microenvironment
2021
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
2019
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
2012 Standout
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
2022 StandoutScienceNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
RNA-Based Vaccines in Cancer Immunotherapy
2015
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
2008
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
2014
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70
2013
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
2012
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient
2014
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
From the RNA world to the clinic
2016 Science
Immune Therapy for Cancer
2008
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
2012
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
2015
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
2014
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
2008
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
2013
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
2013
Works of Bart Neyns being referenced
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
2018
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
2016
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
2010
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
2014
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
2013
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
2007
Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens
2012
Current approaches in dendritic cell generation and future implications for cancer immunotherapy
2007
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
2014
Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
2012
Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients
2012
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient
2011
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
2019
Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient
2011
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
2009
Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA
2008
Immunotherapy of Cancer with Dendritic Cells Loaded with Tumor Antigens and Activated Through mRNA Electroporation
2010
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
2017
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
2012
Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
2011
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients
2013
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
2014
Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
2005
Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells
2004
CONTAMINANTS WITHIN BACTERIAL PLASMID PREPARATIONS TRIGGER APOPTOSIS IN LIPOSOME TRANSFECTED OVCAR3, BUT NOT IN SKOV3 OR AZ224 HUMAN OVARIAN CANCER CELLS
2001
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
2014
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
2009
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma.
2014
Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials.
2013
Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.
2016
Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells
2008
Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity
2009
9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors
2009
Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
2020
A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy
2014
Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
2018
Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
2008
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials
2012
Characterization of CD8+T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
2013
Mature results of a phase I/IIA trial of the integrin inhibitor cilengitide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy (TMZ/RT) for newly diagnosed glioblastoma (GBM)
2007
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
2018
Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels
2009
Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
2018
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
2012
Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)
2007
Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.
2013
Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients
2009